Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
Phase 3 OCEANIC-STROKE data showed asundexian plus antiplatelet therapy reduced recurrent ischemic stroke versus placebo. Major bleeding rates were similar between groups.
A study of over 600,000 patients reveals GLP-1 drugs may reduce addiction across multiple substances, with 50% fewer substance-related deaths and significant reductions in overdoses and hospitalizations. The drugs work by dampening dopamine signaling in brain reward centers. Researchers are exploring broader applications for these medications beyond diabetes and obesity treatment.
Oral semaglutide demonstrated significant improvements in multiple cardiometabolic risk factors in adults with type 2 diabetes at high cardiovascular risk. The SOUL trial analysis showed reductions in systolic blood pressure, cholesterol, triglycerides, HbA1c, and body weight compared to placebo. These benefits were observed as early as 13 weeks and contributed to a 14% reduction in major adverse cardiovascular events.
Novo Nordisk received FDA approval for a 7.2-mg semaglutide dose marketed as Wegovy HD for adult patients with obesity who have tolerated the standard 2.4-mg dose. The approval came through the FDA's new Commissioner's National Priority Voucher pilot program.
A systematic review and meta-analysis demonstrates that semaglutide significantly reduces major adverse cardiovascular events in adults with type 2 diabetes, with particular benefits for nonfatal myocardial infarction and stroke.
A secondary analysis of the SOUL trial shows oral semaglutide significantly lowers heart failure-related events in type 2 diabetes patients with preexisting heart failure, particularly those with preserved ejection fraction, without increasing serious adverse events.
Oral semaglutide reduced heart failure events by 22% in Type 2 diabetes patients with existing heart failure in a trial of nearly 9,650 adults, with particular benefit in HFpEF cases.
UK and Brazil issue warnings about possible pancreatitis link to GLP-1 weight-loss drugs, while WADA monitors their use in Olympic athletes amid concerns about muscle loss and performance effects.
New research shows semaglutide cuts cardiovascular event risk by 4% per 5kg weight loss, with two-thirds of heart benefits unexplained by weight reduction alone. Study of 17,604 participants suggests multiple protective mechanisms beyond weight loss.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07212751 |
Coronary CT Angiogram - Prognostic Value of Adverse Plaque Features in Guiding Treatment (CT-PLAQUE) |
ACTIVE_NOT_RECRUITING | |
| NCT06583161 |
Emulation of the Moderate Alcohol and Cardiovascular Health Trial (MACH15) |
COMPLETED | |
| NCT06545799 |
Construction of a Cohort for Pan-Vascular Disease Among Employees of Taizhou People's Hospital |
NOT_YET_RECRUITING | |
| NCT05331547 |
BioFreedom™ BA9™ Ultra |
UNKNOWN | |
| NCT03939624 |
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events |
COMPLETED | |
| NCT03654157 |
ACS Registry - A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow |
COMPLETED | |
| NCT01859897 |
A Prospective Multicenter Study to Evaluate Usefulness of Cardio-Ankle Vascular Index in Japan |
COMPLETED | |
| NCT01225562 |
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin |
COMPLETED | PHASE3 |
| NCT00651222 |
Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy |
COMPLETED |
